ReviewJournal of neurology2026
What is new in Freezing of Gait?
Review in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Freezing of Gait (FOG) research is entering a rapidly evolving phase. Published in early 2026, the International Consortium for FOG (ICFOG) released updated clinical and technical definitions of FOG and introduced a consensus-based standardized testing protocol, the Giladi protocol (GP-FOG), which is currently still under evaluation in an ongoing study. Complementing these advances, two new outcome measures, the clinician-reported outcome (ClinRO) and the patient-reported outcome (PRO), are highlighted in this review. Recent technological developments in both detection and potential prevention of FOG are moving the field toward individualized, biomarker-based, on-demand treatment strategies. In addition, emerging insights into the pathophysiological mechanisms of FOG, particularly nondopaminergic contributions, are discussed. Together, these developments provide a contemporary framework for improving the assessment, understanding, and personalized management of FOG in Parkinson's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.